Investor Presentations

To download, please click below.

executive summary

Vaxil Overview – Executive Summary

AACR 2017 Poster – Immucin Acts as Novel Neoantigen

Vaxil – AACR Poster – Immucin Acts as True Neoantigen

Cancer & Multiple Myeloma

Cancer is the leading cause of death worldwide, accounting for 8,000,000 deaths per annum and 12,000,000 new cases. Multiple Myeloma (MM) is the second-most common blood cancer, in which plasma cells accumulate in bone marrow leading to bone destruction and marrow failure. MM accounts for 1% of all cancers and is still considered incurable given the vast majority of patients eventually relapse. A better approach is desperately needed.

Vaxil™ was founded by Weizmann Institute scientists, Israel's top research university, in order to provide an altogether novel approach to immunotherapy. Vaxil™ has diligently advanced its immunotherapy platform and published its research and clinical results in top medical journals.

The whole story

Prior Immunotherapy Deals

Vaxil Canada
First Canadian Place, 34th Floor, 100 King Street W., Toronto, Ontario. M2N 6N4 Canada

Vaxil Israel
3 Pinhas Sapir Street, 3rd Floor, Weizmann Science Park, 74140, Rehovot, Israel

Corporate

Home
About Vaxil
Vaxil Locations
Contact Us
Board & Executives
News and Updates

INVESTORS

Investor Presentations
Public Filings
News and Updates
In the Media
Video
Scientific Publications

Copyright 2025 © VAXIL BIO THERAPEUTICS | Vaxil Bio therapeutics is an Israeli biotech focused on cancer immunotherapy, based in the Weizmann Science Park in Rehovot, Israel. Vaxil is listed on the TSX-Venture as VXL

About Vaxil
TEAM
INTELLECTUAL PROPERTY
News and Updates
In the Media
2025 Shareholder Meeting Material

Vaxil Locations
Contact Us
Subscribe